hepatocellular carcinoma with portal vein tumor thrombosis
Conditions
Interventions
B:TACE+125I seed implantation
Sponsors
Henan Cancer hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients confirmed by histology and cytology or accord with standard of clinical diagnosis standard; 2. Expected survival time for 3 months or more; 3. Aged 18-75 years old; 4. Generally condition is good and ECOG status score 0 to 2 points; 5. Intrahepatic primary sites for giant block or nodules; 6. Accompanied by portal vein type I or II tumor emboli (left main or right main tumor emboli or at the same time there is two main branch and portal venous tumor emboli but not assault trunk); 7. patients with Child A or B liver function and BCLC stage for C and no bone, brain, lung and lymph node metastasis; 8. Without radiotherapy, chemotherapy, biological treatment history; 9. No serious complications such as renal insufficiency, cardiac insufficiency, and?no serious iodine allergy; 10. Patients with informed consent and good adherence to follow-up.
Exclusion criteria
Exclusion criteria: 1. In addition to its portal vein tumor distant metastasis; 2. Biliary tract tumor invasion to biliary obstruction; 3. Brain metastases or have symptoms of brain metastases and without further examination excluded patients; 4. Diffuse liver tumors; 5. The tumor load > 50%; 6. Portosystemic shunts or liver blood vessels - venous fistula; 7. Congestive heart failure > New York heart association (NYHA) class 2 and have no control of high blood pressure; 8. A history of human immunodeficiency virus (HIV) infection; 9. Kidney failure or renal insufficiency, and need for blood or peritoneal dialysis; 10. Target lesion before receiving any treatment; 11. Severely active clinical infection (> 2 levels, NCI CTCAE version 4.0), except for HBV and HCV infection; 12. Upper gastrointestinal bleeding within 4 weeks before starting test or there is a clear tendency of gastrointestinal bleeding; 13. Sorafenib or Doxorubicin or Pirarubicin taboo; 14. The patient in pregnancy or breastfeeding; 15. Women in childbearing age and the spouses ?must be taken?contraceptive measures; 16. Within 4 weeks before start test received other molecular targeted drugs treatment; 17. Four weeks before ?experimenting began?there were ?surgery ?(eg: in the chest and abdominal or pelvic cavity) or has not yet recovered from a side effect of this kind of surgery patients; 18. With other malignant tumors ( have cured three years ago can be included); 19. Previons received systemic chemotherapy; 20. Previons treated with radical therapy (surgery, liver transplantation, ablation) patients must have a new target lesions; 21. Previous received TACE treatment, the original lesions was not as target lesions, the group must have a new target lesions.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall Survival; | — |
Countries
China
Contacts
Public ContactHailiang Li
Outcome results
None listed